{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:24:21Z","timestamp":1787217861543,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"[talents program of Jiangsu Cancer Hospital] under Grant","award":["number YC201801"],"award-info":[{"award-number":["number YC201801"]}]},{"name":"[key project of Jiangsu Commission of Health] under Grant","award":["number K2023021"],"award-info":[{"award-number":["number K2023021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-026-02552-4","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:47:12Z","timestamp":1783514832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["18F-FDG PET\/CT radiomics combined with double-expressor status enhances prognostication and high-risk stratification in DLBCL"],"prefix":"10.1186","volume":"26","author":[{"given":"Qi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faquan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"6","key":"2552_CR1","first-page":"351","volume":"47","author":"AT Skarin","year":"1997","unstructured":"Skarin AT, Dorfman DM. Non-Hodgkin\u2019s lymphomas: current classification and management. CA Cancer J Clin. 1997;47(6):351\u201372.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"2552_CR2","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.1093\/oncolo\/oyad069","volume":"28","author":"Z Musimar","year":"2023","unstructured":"Musimar Z, Mpetani M, Abramson JS, et al. Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study. Oncologist. 2023;28(9):e756\u201364.","journal-title":"Oncologist"},{"issue":"5","key":"2552_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol. 2021;96(5):617\u201329.","journal-title":"Am J Hematol"},{"issue":"1","key":"2552_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41408-023-00970-z","volume":"14","author":"ERA Pennings","year":"2024","unstructured":"Pennings ERA, Durmaz M, Visser O, et al. Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands. Blood Cancer J. 2024;14(1):3.","journal-title":"Blood Cancer J"},{"issue":"16","key":"2552_CR5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood"},{"issue":"21","key":"2552_CR6","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1200\/JCO.21.02063","volume":"40","author":"NG Mikhaeel","year":"2022","unstructured":"Mikhaeel NG, Heymans MW, Eertink JJ, et al. Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. J Clin Oncol. 2022;40(21):2352\u201360.","journal-title":"J Clin Oncol"},{"issue":"14","key":"2552_CR7","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20\u2009+\u2009B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373\u201380.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2552_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1186\/s12885-024-12668-x","volume":"24","author":"S Cui","year":"2024","unstructured":"Cui S, Xin W, Wang F, et al. Metabolic tumour area: a novel prognostic indicator based on (18)F-FDG PET\/CT in patients with diffuse large B-cell lymphoma in the R-CHOP era. BMC Cancer. 2024;24(1):895.","journal-title":"BMC Cancer"},{"issue":"5","key":"2552_CR9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857\u201361.","journal-title":"Blood"},{"issue":"23","key":"2552_CR10","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"AS Ruppert","year":"2020","unstructured":"Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041\u20138.","journal-title":"Blood"},{"issue":"1","key":"2552_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275\u201382.","journal-title":"Blood"},{"issue":"10","key":"2552_CR12","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.2967\/jnumed.124.267784","volume":"65","author":"J van Sluis","year":"2024","unstructured":"van Sluis J, van Snick JH, Glaudemans A, et al. Ultrashort Oncologic Whole-Body [(18)F]FDG Patlak Imaging Using LAFOV PET. J Nucl Med. 2024;65(10):1652\u20137.","journal-title":"J Nucl Med"},{"issue":"7","key":"2552_CR13","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1080\/10428194.2020.1728750","volume":"61","author":"G Delaby","year":"2020","unstructured":"Delaby G, Hubaut MA, Morschhauser F, et al. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline (18)F-FDG PET-CT. Leuk Lymphoma. 2020;61(7):1584\u201391.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2552_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","volume":"32","author":"AS Cottereau","year":"2021","unstructured":"Cottereau AS, Meignan M, Nioche C, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT(\u2020). Ann Oncol. 2021;32(3):404\u201311.","journal-title":"Ann Oncol"},{"issue":"7","key":"2552_CR15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00259-019-04309-4","volume":"46","author":"QA Shagera","year":"2019","unstructured":"Shagera QA, Cheon GJ, Koh Y, et al. Prognostic value of metabolic tumour volume on baseline (18)F-FDG PET\/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging. 2019;46(7):1417\u201327.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"50","key":"2552_CR16","doi-asserted-by":"publisher","first-page":"83544","DOI":"10.18632\/oncotarget.13180","volume":"7","author":"M Zhou","year":"2016","unstructured":"Zhou M, Chen Y, Huang H, et al. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in diffuse large B-cell lymphoma. Oncotarget. 2016;7(50):83544\u201353.","journal-title":"Oncotarget"},{"issue":"1","key":"2552_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.119.229450","volume":"61","author":"AS Cottereau","year":"2020","unstructured":"Cottereau AS, Nioche C, Dirand AS, et al. (18)F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome. J Nucl Med. 2020;61(1):40\u20135.","journal-title":"J Nucl Med"},{"issue":"1","key":"2552_CR18","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1186\/s12885-023-11333-z","volume":"23","author":"F Wang","year":"2023","unstructured":"Wang F, Cui S, Lu L, et al. Dissemination feature based on PET\/CT is a risk factor for diffuse large B cell lymphoma patients outcome. BMC Cancer. 2023;23(1):1165.","journal-title":"BMC Cancer"},{"issue":"12","key":"2552_CR19","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.2967\/jnumed.121.263501","volume":"63","author":"KB Girum","year":"2022","unstructured":"Girum KB, Rebaud L, Cottereau AS, et al. (18)F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients. J Nucl Med. 2022;63(12):1925\u201332.","journal-title":"J Nucl Med"},{"issue":"9","key":"2552_CR20","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1038\/s41375-025-02688-2","volume":"39","author":"R Dondolin","year":"2025","unstructured":"Dondolin R, Garrou F, Almasri M, et al. Integration of [(18)F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma. Leukemia. 2025;39(9):2207\u201314.","journal-title":"Leukemia"},{"issue":"28","key":"2552_CR21","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","volume":"30","author":"TM Green","year":"2012","unstructured":"Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460\u20137.","journal-title":"J Clin Oncol"},{"issue":"24","key":"2552_CR22","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1002\/cncr.31646","volume":"124","author":"PA Riedell","year":"2018","unstructured":"Riedell PA, Smith SM. Double hit and double expressors in lymphoma: Definition and treatment. Cancer. 2018;124(24):4622\u201332.","journal-title":"Cancer"},{"key":"2552_CR23","doi-asserted-by":"crossref","unstructured":"Han B, Kim S, Koh J et al. Immunophenotypic Landscape and Prognosis of Diffuse Large B-Cell Lymphoma with MYC\/BCL2 Double Expression: An Analysis of A Prospectively Immunoprofiled Cohort. Cancers (Basel) 2020, 12(11).","DOI":"10.3390\/cancers12113305"},{"issue":"1","key":"2552_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","volume":"35","author":"AF Herrera","year":"2017","unstructured":"Herrera AF, Mei M, Low L, et al. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017;35(1):24\u201331.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2552_CR25","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3109\/10428194.2015.1096352","volume":"57","author":"K Miura","year":"2016","unstructured":"Miura K, Takahashi H, Nakagawa M, et al. Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy. Leuk Lymphoma. 2016;57(6):1335\u201341.","journal-title":"Leuk Lymphoma"},{"issue":"9\u201310","key":"2552_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1080\/0284186X.2016.1189093","volume":"55","author":"M Abdulla","year":"2016","unstructured":"Abdulla M, Laszlo S, Triumf J, et al. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients. Acta Oncol. 2016;55(9\u201310):1126\u201331.","journal-title":"Acta Oncol"},{"key":"2552_CR27","doi-asserted-by":"crossref","unstructured":"Hwang J, Suh C, Kim K et al. The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021, 13(13).","DOI":"10.3390\/cancers13133369"},{"issue":"Suppl 1","key":"2552_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/hon.2399","volume":"35","author":"L Quintanilla-Martinez","year":"2017","unstructured":"Quintanilla-Martinez L. The 2016 updated WHO classification of lymphoid neoplasias. Hematol Oncol. 2017;35(Suppl 1):37\u201345.","journal-title":"Hematol Oncol"},{"key":"2552_CR29","unstructured":"Zelenetz AD, Gordon LI, Abramson JS et al. NCCN Guidelines\u00ae Insights: B-Cell Lymphomas 3.2025. J Natl Compr Canc Netw 2025, 23(10)."},{"issue":"16","key":"2552_CR30","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S, et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018;78(16):4786\u20139.","journal-title":"Cancer Res"},{"issue":"2","key":"2552_CR31","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2552_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2967\/jnumed.119.238923","volume":"62","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Zwezerijnen B, de Vet HCW, et al. Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium. J Nucl Med. 2021;62(3):332\u20137.","journal-title":"J Nucl Med"},{"key":"2552_CR33","doi-asserted-by":"crossref","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048\u201358.","DOI":"10.1200\/JCO.2013.53.5229"},{"issue":"27","key":"2552_CR34","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2552_CR35","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1007\/s00259-021-05233-2","volume":"48","author":"R Frood","year":"2021","unstructured":"Frood R, Burton C, Tsoumpas C, et al. Baseline PET\/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review. Eur J Nucl Med Mol Imaging. 2021;48(10):3198\u2013220.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2552_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s13139-022-00782-2","volume":"57","author":"JH Jo","year":"2023","unstructured":"Jo JH, Chung HW, Kim SY, et al. FDG PET\/CT Maximum Tumor Dissemination to Predict Recurrence in Patients with Diffuse Large B-Cell Lymphoma. Nucl Med Mol Imaging. 2023;57(1):26\u201333.","journal-title":"Nucl Med Mol Imaging"},{"issue":"7","key":"2552_CR37","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2552_CR38","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00259-018-3966-7","volume":"45","author":"N Aide","year":"2018","unstructured":"Aide N, Lasnon C, Damaj G. Combining baseline TMTV and gene profiling for a better risk stratification in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(5):677\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2552_CR39","first-page":"1876","volume":"65","author":"VKJ Vergote","year":"2024","unstructured":"Vergote VKJ, Verhoef G, Janssens A, et al. International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume\u2013Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma. J Nucl Med. 2024;65(12):1876\u201383.","journal-title":"J Nucl Med"},{"issue":"5","key":"2552_CR40","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1007\/s00259-022-06075-2","volume":"50","author":"M Winkelmann","year":"2023","unstructured":"Winkelmann M, Blumenberg V, Rejeski K, et al. Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy. Eur J Nucl Med Mol Imaging. 2023;50(5):1406\u201313.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2552_CR41","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41408-025-01338-1","volume":"15","author":"M Winkelmann","year":"2025","unstructured":"Winkelmann M, Raj SS, Jain MD, et al. Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma. Blood Cancer J. 2025;15(1):144.","journal-title":"Blood Cancer J"},{"key":"2552_CR42","doi-asserted-by":"crossref","unstructured":"Cottereau AS, Meignan M, Nioche C et al. New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET\/CT. Cancers (Basel) 2021, 13(16).","DOI":"10.3390\/cancers13163998"},{"issue":"1","key":"2552_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3960\/jslrt.51.7","volume":"51","author":"N Tomita","year":"2011","unstructured":"Tomita N. BCL2 and MYC dual-hit lymphoma\/leukemia. J Clin Exp Hematop. 2011;51(1):7\u201312.","journal-title":"J Clin Exp Hematop"},{"issue":"6","key":"2552_CR44","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjh.12982","volume":"166","author":"Y Oki","year":"2014","unstructured":"Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891\u2013901.","journal-title":"Br J Haematol"},{"issue":"28","key":"2552_CR45","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2552_CR46","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/cas.16377","volume":"116","author":"YF Wu","year":"2025","unstructured":"Wu YF, Yuan QH, Shen HR, et al. The prognostic significance of MYC\/BCL2 double expression in DLBCL in the genetic classification era. Cancer Sci. 2025;116(1):257\u201370.","journal-title":"Cancer Sci"},{"issue":"7","key":"2552_CR47","doi-asserted-by":"publisher","first-page":"e0307253","DOI":"10.1371\/journal.pone.0307253","volume":"19","author":"P Yimpak","year":"2024","unstructured":"Yimpak P, Bumroongkit K, Tantiworawit A, et al. Immunohistochemistry-based investigation of MYC, BCL2, and Ki-67 protein expression and their clinical impact in diffuse large B-cell lymphoma in upper Northern Thailand. PLoS ONE. 2024;19(7):e0307253.","journal-title":"PLoS ONE"},{"issue":"4","key":"2552_CR48","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s00259-021-05572-0","volume":"49","author":"X Zhang","year":"2022","unstructured":"Zhang X, Chen L, Jiang H, et al. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [(18)F]FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2022;49(4):1298\u2013310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2552_CR49","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/neuonc\/not236","volume":"16","author":"K Han","year":"2014","unstructured":"Han K, Ren M, Wick W, et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 2014;16(5):696\u2013706.","journal-title":"Neuro Oncol"},{"issue":"25","key":"2552_CR50","first-page":"3055","volume":"141","author":"JJ Eertink","year":"2023","unstructured":"Eertink JJ, Zwezerijnen GJC, Heymans MW, et al. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood. 2023;141(25):3055\u201364.","journal-title":"Blood"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02552-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02552-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02552-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:32:59Z","timestamp":1787214779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-026-02552-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2552"],"URL":"https:\/\/doi.org\/10.1186\/s12880-026-02552-4","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part are appropriately investigated and resolved. This study was performed in accordance with the principles of the Declaration of Helsinki. This was a retrospective study using de-identified clinical data, with no patient intervention or privacy disclosure involved. The study was reviewed and approved by the Ethics Committee of Jiangsu Cancer Hospital (Approval No.: KY-2025-095; Approval Date: 16 July 2025). Informed consents were obtained from all patients.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"413"}}